Literature DB >> 9657236

Paroxetine: a review of clinical experience.

D Dunner1, R Kumar.   

Abstract

The selective serotonin reuptake inhibitor paroxetine has been extensively studied and is now an established therapy for the treatment of depressive disorders. Paroxetine has demonstrated efficacy in major depression in both young and elderly patients, with an improved tolerability profile over conventional antidepressants. Paroxetine is effective across a continuum of anxiety and depressive disorders, including severe depression, depression with anxiety, comorbid depression and obsessive-compulsive disorder. The first agent of its class licensed for use in panic disorder, paroxetine has been shown to be effective in reducing the number of panic attacks and preventing relapse. A worldwide clinical database has established that paroxetine has a benign adverse event profile. Paroxetine therefore offers an effective and well tolerated treatment for a broad spectrum of psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657236     DOI: 10.1055/s-2007-979307

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  3 in total

1.  Sertraline and alprazolam in the treatment of panic desorder.

Authors:  Saida Fiseković; Svjetlana Loga-Zec
Journal:  Bosn J Basic Med Sci       Date:  2005-05       Impact factor: 3.363

Review 2.  Paroxetine: an update of its use in psychiatric disorders in adults.

Authors:  Antona J Wagstaff; Susan M Cheer; Anna J Matheson; Douglas Ormrod; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Paroxetine-induced modulation of cortical activity supporting language representations of action.

Authors:  Patrice Péran; Jean-François Démonet; Dominique Cardebat
Journal:  Psychopharmacology (Berl)       Date:  2007-09-18       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.